Tag: the war on (some) drugs

Texas Hemp THC Ban and Medical Marijuana Expansion Set to Become Law on Monday

With the deadline for gubernatorial action falling on Sunday, June 22, both bills are now expected to become law without Abbott’s signature unless he issues a rare weekend veto.

If no veto is delivered by the end of Sunday, the measures will automatically take effect. House Bill 46 would significantly broaden the state’s limited compassionate use program by adding eligibility for patients with chronic pain, terminal illness, and traumatic brain injuries. It would also expand the number of licensed dispensaries from three to fifteen and legalize new product forms, such as patches and inhalers.

Senate Bill 3 would prohibit nearly all hemp-derived THC products—including delta-8, delta-10, and THCO—when intended for ingestion, inhalation, or topical use. Only trace THC amounts would be allowed in non-intoxicating products like CBD. If enacted, the ban would deal a major blow to Texas’ multibillion-dollar hemp THC industry. The restrictions would take effect September 1.

Despite both bills passing with strong bipartisan support, Abbott said earlier this week that he was still undecided on the hemp ban. With time running out, stakeholders are bracing for the likelihood that both measures will quietly become law on Monday, June 23.

Keep reading

“What in the World Would Justify Doing This?”: A Texas Vet and Hemp-Business Owner on the Looming THC Ban

By Sunday, Texans will know whether the hemp-derived THC products that have been legal in the state since 2019 will be banned as of September 1. During the Eighty-Ninth Legislature, lawmakers passed Senate Bill 3, which would end a $5.5 billion industry and which now sits on Governor Greg Abbott’s desk. Sunday is the deadline for him to either veto the bill—breaking with Lieutenant Governor Dan Patrick, who made SB 3 a priority during the session and pushed it through both chambers with zeal—or allow it to become law. 

Lukas Gilkey, an Austin-based U.S. Coast Guard veteran, cofounded the cannabis company Hometown Hero, which has been producing hemp-derived THC products since 2019, and has emerged as one of the most outspoken opponents of the ban. The 44-year-old has gone viral for his social media posts responding to Patrick and defending the industry. With just days to go before Abbott determines the fate of the industry, we asked him to explain his position and make his pitch to the governor for why weed is good for Texas.  

Texas Monthly: So there’s an argument that legalization of these products in 2019 was kind of an accident: The Legislature legalized hemp, mirroring language that appeared in the federal farm bill the previous year, and in the process allowed the proliferation of certain derivatives that it did not consider. And so the argument goes that what it has done this session is just correcting an oversight. Does that hold water for you? 

Lukas Gilkey: Knowingly or unknowingly, they legalized these products, and subsequently a fully legal industry was created from that decision. This industry has over four billion dollars in retail sales in Texas. It’s created over 53,000 jobs, over eight thousand small businesses. If they wanted to correct it, it should have been done much sooner, rather than letting so many Texans enter this industry under the assumption it was legal and the politicians were okay with it. They allowed this thing to grow and then changed their mind six years later when they could have done it in 2021. Why did they not? 

Keep reading

Texas medical marijuana companies spent big on Republican lobbyists to push THC ban

Gov. Greg Abbott has a choice when it comes to banning hemp-derived delta-8 and delta-9 THC products: listen to hundreds of thousands of Texans who enjoy them or a handful of powerful Republican lobbyists working for marijuana investors.

Abbott is in the crossfire of a cannabis civil war. Medical marijuana and retail hemp companies are fighting over who can legally get people high. The standoff is typical Texas politics, with the medical marijuana companies hiring former aides to Abbott and Lt. Gov Dan Patrick to lobby for them, and the hemp industry relying on public pressure.

The Texas Legislature authorized medical marijuana in 2017 for a tiny number of patients. Three medical cannabis companies have spent millions complying with the Texas Compassionate Use Program to legally sell products with THC, the ingredient in marijuana that makes you high. They expected exclusivity. Since then, lawmakers have steadily expanded TCUP to treat more conditions, adding people with chronic pain this year.

In 2021, cannabis-focused venture capital firm AFI Capital Partners led a $21 million Series B investment in Texas Original Compassionate Cultivation. The company supplied 77% of the medical cannabis consumed in 2022, the latest full-year data available in an annual Texas Department of Public Safety TCUP analysis.

The investment had horrible timing. In 2019, federal and state lawmakers legalized hemp, a type of cannabis with low levels of THC. Hemp entrepreneurs figured out how to concentrate the THC, and today, the hemp industry primarily sells edibles containing enough THC to get you stoned.

Keep reading

Veterans deserve change. US should reschedule cannabis now.

When our nation’s heroes return home, they often face a quiet suffering — something I have seen happen so often in my peers. As a combat veteran and an advocate for those who have worn the uniform, I know that so many of us face these challenges long after we return home. Post-traumatic stress (PTS) is a battlefield of its own — invisible, relentless, and too often fought alone.

Over the years, I’ve dedicated my life to improving the lives of our veterans, whether serving as a Veterans Fellow and Lead Policy Advisor on Military and Veterans Affairs to Sen. Chuck Grassley, leading within the Iowa Veterans of Foreign Wars (VFW), or conducting academic research focused on veterans’ issues. One thing has become undeniably clear: it’s time to reschedule cannabis as a Schedule III substance under federal law, a change that is backed by President Donald Trump, which would open the door for unlocking its therapeutic potential for veterans suffering from PTS and other chronic illnesses.

Currently, cannabis remains a Schedule I substance — the same category as heroin — defined as having “no accepted medical use” and a “high potential for abuse.” This is not only scientifically outdated, but also morally indefensible. Veterans are not asking for a miracle cure. We are asking for options. We are asking for the freedom to explore alternative treatments when conventional therapies — prescription medications, talk therapy, or exposure therapy — fall short. For many veterans, they do. And for some, cannabis has helped where nothing else has.

Keep reading

High Doses Of LSD Lead To ‘Greater Reductions In Depression’ Compared To Low Doses Of The Psychedelic, New Study Finds

Taking a high dose of LSD, coupled with assisted therapy, led to “greater reductions in depression” among patients compared to those who received a low dose of the psychedelic, according to a new study.

Researchers at the University of Basel in Switzerland investigated the therapeutic potential of LSD for people with moderate-to-severe major depressive disorder, and they found the substance showed “promise” as a “novel approach” to treating the condition.

Notably, the study—published this month in the journal Med—indicated that “high-dose-LSD-assisted therapy reduced depressive symptoms more than low-dose therapy” and that the improvements lasted for up to 12 weeks after the treatment.

The randomized, double-blind trial involved administering doses of 100μg and 200μg of LSD for one cohort and two doses of 25μg of the psychedelic for the other. Symptoms of depression were measured at multiple intervals, starting with the baseline and followed up with examinations after two weeks, six weeks and 12 weeks.

After assessing the 61 patients post-administration, the researchers concluded that the “findings of this exploratory study support further investigation of LSD-assisted therapy in depression in a larger phase 3 trial.”

“The present trial’s strengths include a clinically representative sample with respect to the duration of illness, common comorbid conditions, and various pretreatments,” the study authors said. “Other strengths include the comparison with a low-dose group and a relatively long follow-up period of 12 weeks after the last administration.”

“LSD could be used safely within the framework of this study,” they said, adding that compared to previous trials involving psilocybin, “LSD has a longer duration of action.”

“This prolonged effect makes clinical application more resource intensive. It remains to be resolved whether this extended duration offers clinical advantages,” the study text says. “Furthermore, it is yet to be determined if there are other relevant differences among hallucinogenic drugs in terms of therapeutic potential.”

Keep reading

DEA Judge Shuts Down Cannabis Manufacturing Case Without Hearing, Company Plans Legal Challenge

The company behind the application, MMJ BioPharma Cultivation, is now preparing to challenge the ruling in federal court and call for the judge’s recusal.

The ruling was issued by DEA Chief Administrative Law Judge John Mulrooney II, who dismissed the company’s bid for a marijuana bulk manufacturing license after more than six years of delays. MMJ BioPharma said the decision came without warning and without any opportunity to present evidence or respond to agency claims—calling it a “procedural ambush.”

“This isn’t regulation—it’s an illegal ambush,” said MMJ CEO Duane Boise, who said the company had complied with all requirements under the Controlled Substances Act and FDA pathways.

MMJ, which is developing cannabis-based medicines for Huntington’s disease and multiple sclerosis, submitted a legally binding supply agreement in March 2024 with a DEA-licensed Schedule I facility. The agreement included specific sourcing protocols, defined volume, and DEA Form 222 compliance. Despite that, Mulrooney’s June 16 ruling ignored the document entirely and blocked it from being entered into the record.

Boise accused the DEA of demanding the agreement and then refusing to acknowledge it once submitted. “The agency cannot demand a document, receive it, then declare it irrelevant behind closed doors,” he said.

The order also reversed a previous determination by another administrative judge that certain disputed facts warranted a hearing. Instead, Mulrooney cited internal communications from a DEA investigator that MMJ was never allowed to challenge or respond to—raising concerns of ex parte communications and due process violations.

Keep reading

Why Is Texas Supporting Psychedelics Research While Criminalizing Cannabis?

Texas just announced it will invest $50 million into studying ibogaine, a powerful psychedelic drug that remains illegal at the federal level. The goal? To develop it into a potential Food and Drug Administration-approved treatment for conditions like opioid use disorder, PTSD and depression; especially among veterans.

On the surface, this might sound like a bold and progressive move. But here’s the irony: at the very same time, Texas continues to criminalize cannabis and might soon even outlaw hemp-derived THC products.

Let’s break this down. Cannabis, a plant with centuries of use, decades of medical data and broad public support remains illegal for adult use in Texas. Despite overwhelming national support for legalization—a staggering 88 percent of Americans now back medical or recreational cannabis use)—the state has chosen to double down on prohibition, with lawmakers sending Gov. Greg Abbott (R) a bill that would outlaw consumable hemp products with any traces of THC. He has until Sunday to decide whether to allow that ban to take effect.

Even worse, prohibition isn’t stopping anything. The black market is thriving in Texas. Cartels and illicit operators flood the state with unregulated, untested cannabis. No taxes are collected, no consumer protections exist and legal hemp retailers are now being threatened. It is a misguided public safety argument deluded by a lack of facts and science, political conservatism, contradictory business objectives and outdated stigmas.

Meanwhile, ibogaine, a hallucinogenic alkaloid that can induce intense psychedelic experiences, is now the subject of a $50 million state-funded research push. The same lawmakers who claim cannabis is too dangerous and not well studied are throwing their support behind a compound with far less research and much more uncertainty with the intent of studying it.

This isn’t a critique of psychedelic medicine. Ibogaine may very well hold incredible therapeutic value. But if Texas is willing to support cutting-edge, controversial treatments for serious mental health and addiction issues, why not start with widely available data and access to cannabis? Cannabis has already been shown to help with chronic pain, anxiety, sleep, seizures and opioid dependency.

Keep reading

75,000 pounds of THC products seized in DFW raids as Texas Gov. Abbott weighs statewide ban

Police raided locations across DFW on Tuesday in a year-long investigation into THC sales. 

The Allen Police Department, with help from the DEA, seized products at three warehouses in Dallas, while other agencies raided the owners’ homes in Carrollton, Colleyville, and Plano.

Allen’s police chief took the CBS News Texas crew inside one of the warehouses as officers pulled products off the shelves. 

According to early estimates from Allen PD, investigators seized over 75,000 pounds of THC products and $7 million worth of cash and assets in Tuesday’s raids.   

Chief Steve Dye said the warehouse raids are the product of an investigation that began more than a year ago with undercover purchases at shops in Allen. The I-Team documented how the Allen Police Department’s narcotics unit bought and tested the items ahead of raids at nine stores last August. Investigators said the illegal products found in Allen are being supplied by the warehouses in Dallas. 

“You don’t have to go to your drug dealer anymore to buy drugs,” said Dye. “You can go to a vape shop on any corner.” 

He believes the products found on store shelves are more dangerous than illegal drugs because, Dye said, the false sense of safety has led to an explosion in use.

Keep reading

Ohio GOP Lawmakers Can’t Agree On How To Amend Marijuana Law, Causing Planned Vote To Be Canceled

Despite efforts in the Ohio legislature to pass a bill to significantly change the state’s voter-approved marijuana law, last-minute disagreements between the House and Senate Republicans seemed to have derailed that plan for now—with House lawmakers signaling that a deal won’t be struck before the summer recess.

After taking public testimony and adopting certain changes to the Senate-passed legislation, SB 56, in recent weeks, the House Judiciary Committee ultimately declined to advance the proposal as scheduled at a Wednesday hearing, making it so the measure couldn’t advance to a floor vote planned for that day. Evidently, the revisions didn’t sit well with key senators, according to several legislators.

“Apparently the Senate changed their mind,” Rep. Jamie Callender (R), a pro-legalization lawmaker, told News 5 Cleveland.

Changes approved at a hearing late last month, for example, rolled back some of the strict limits included in a version of the measure passed by the Senate in February, including a criminal prohibition on sharing marijuana between adults on private property.

“They wanted to make a mandatory jail sentence for passing a joint between friends,” Callender, who has spent weeks working on additional changes to the legislation, said. He also complained about the Senate’s proposal to put all cannabis tax revenue in the state’s general fund, which would have prevented local municipalities from getting a share of those dollars as is currently the law.

Keep reading

Federal Bill Would ‘Effectively’ Ban All Consumable Hemp Products—’Including CBD’—Congressional Researchers Say

A federal spending bill that’s advancing in the House would “effectively” prohibit hemp-derived cannabinoid products, including CBD, congressional researchers say.

In a report published by the Congressional Research Service (CRS) last week, legislative analysts looked at the potential impact of hemp-related provisions that advocates and stakeholders say would devastate a core sector of the industry.

While report language attached to the 2026 appropriations bill was recently amended to clarify lawmakers’ intent not to disrupt the non-intoxicating cannabinoid market—signaling that products like CBD shouldn’t be banned—the legislation itself hasn’t changed and could still jeopardize the industry without further amendments to its provisions.

The CRS analysis, which came out after the bill’s report language was revised, seems to validate the industry’s concerns about the legislation, explaining how it would “expand on the existing statutory definition of hemp,” which currently means cannabis containing no more than 0.3 percent THC by dry weight, “to include industrial hemp products and exclude hemp-derived cannabinoid products.”

“Excluding hemp-derived cannabinoid products from the federal definition of hemp effectively would prohibit production and sale of hemp-derived cannabinoids, derivatives, and extracts thereof, including cannabidiol (CBD),” it says. “Excluded cannabinoids would cover also non-naturally occurring and synthesized or manufactured compounds.”

“The proposed provision would make other broader changes to the hemp definition by changing the allowable limits of THC—the leading psychoactive cannabinoid in the cannabis plant—to be determined on the basis of its total THC, including tetrahydrocannabinolic acid (THCA), instead of delta-9 THC. This would codify the regulatory practice established in USDA’s 2021 final hemp regulations. The provision would exclude from hemp ‘any viable seeds from a Cannabis sativa L. plant’ that exceed a total THC (including THCA) of 0.3 percent in the plant on a dry weight basis.”

As it stands, the legislation has cleared a House Appropriations subcommittee—but while it was discussed in the full committee last week, members ultimately did not act on it before recessing for a district work period. The panel is set to take the bill back up next week.

Before breaking, however, the full panel did adopt a manager’s amendment to the attached report from Rep. Andy Harris (R-MD), a vocal opponent of cannabis reform. Despite his personal opposition, the revised report clarifies that the panel does not intend to prohibit non-intoxicating cannabinoid products with “trace or insignificant amounts of THC” that were federally legalized during the first Trump administration.

“In determining the quantifiable amounts, the Committee does not intend for industrial or nonintoxicating hemp-derived cannabinoid products with trace or insignificant amounts of THC to be affected,” it says.

Harris said in opening remarks at last week’s hearing that the legislation closes “the hemp loophole from the 2018 Farm Bill.”

Keep reading